BX-517

CAS No. 850717-64-5

BX-517( BX-517 | BX 517 | BX517 | PDK1 inhibitor2 )

Catalog No. M17615 CAS No. 850717-64-5

BX-517 is a potent and selective inhibitor of PDK1.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 67 In Stock
5MG 61 In Stock
10MG 85 In Stock
25MG 147 In Stock
50MG 269 In Stock
100MG 423 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    BX-517
  • Note
    Research use only, not for human use.
  • Brief Description
    BX-517 is a potent and selective inhibitor of PDK1.
  • Description
    BX-517, also known as PDK1 inhibitor2, is a potent and selective PDK1 inhibitor.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    BX-517 | BX 517 | BX517 | PDK1 inhibitor2
  • Pathway
    Metabolic Enzyme/Protease
  • Target
    Retinoid Receptor
  • Recptor
    PDK1
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    850717-64-5
  • Formula Weight
    282.3
  • Molecular Formula
    C15H14N4O2
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO : ≥ 27 mg/mL; 95.64 mM
  • SMILES
    O=C(Nc1cc2c(NC(=O)/C/2=C(\c2ccc[nH]2)/C)cc1)N
  • Chemical Name
    (Z)-N-(3-(1-(1H-pyrrol-2-yl)ethylidene)-2-hydroxy-3H-indol-5-yl)carbamimidic acid

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Islam I, et al. Indolinone based phosphoinositide-dependent kinase-1 (PDK1) inhibitors. Part 2: optimization of BX-517. Bioorg Med Chem Lett. 2007 Jul 15;17(14):3819-25.
molnova catalog
related products
  • Ro 41-5253

    Ro 41-5253 is an orally active RARα antagonist, ligand, and partial agonist of peroxisome proliferator-activated receptor (PPAR)-γ.

  • CD 1530

    CD 1530 is a selective and potent RARγ agonist (Kd:150 nM) with potential anticancer activity, shows insecticidal activity against Cryptobacterium hidradii nematodes, and can be used to study oral carcinogenesis.

  • PA452

    PA452 is a retinoic X receptor (RXR) specific antagonist. PA452 suppresses the effect of Retinoic acid (RA) on Th1/Th2 development.